93 related articles for article (PubMed ID: 35748072)
1. Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible
La YJ; Kim HR; Oh DH; Ahn JY; Kim YC
Yonsei Med J; 2022 Jul; 63(7):611-618. PubMed ID: 35748072
[TBL] [Abstract][Full Text] [Related]
2. Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.
Wong D; Wong T; Romney M; Leung V
BMC Infect Dis; 2016 May; 16():224. PubMed ID: 27215201
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.
Wong D; Wong T; Romney M; Leung V
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():27. PubMed ID: 27112143
[TBL] [Abstract][Full Text] [Related]
4. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
Willekens R; Puig-Asensio M; Suanzes P; Fernández-Hidalgo N; Larrosa MN; González-López JJ; Rodríguez-Pardo D; Pigrau C; Almirante B
J Antimicrob Chemother; 2022 Jul; 77(8):2288-2295. PubMed ID: 35552420
[TBL] [Abstract][Full Text] [Related]
5. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Hess KA; Kooda K; Shulha JA; Mara K; Go JR; Fida M; DeSimone DC; Stevens RW
J Clin Microbiol; 2023 Apr; 61(4):e0003923. PubMed ID: 36988505
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Options for Adult Patients With Persistent Methicillin-Susceptible
Chastain DB; Covert KL; Tu PJ; McDougal S; White BP; Cluck D
Ann Pharmacother; 2023 Nov; 57(11):1312-1327. PubMed ID: 36946576
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline as salvage therapy for methicillin susceptible Staphylococcus aureus complicated bacteremia.
Obed MN; Toresani I; Mykietuk A; Nannini EC
Medicina (B Aires); 2022; 82(5):794-797. PubMed ID: 36220043
[TBL] [Abstract][Full Text] [Related]
10. Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia.
Mohamed A; Bennett N; Ploetz J; Aragon L; Kennedy K; Boyd S
Int J Antimicrob Agents; 2022 Sep; 60(3):106632. PubMed ID: 35787919
[TBL] [Abstract][Full Text] [Related]
11. The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.
Aleissa MM; Gonzalez-Bocco IH; Zekery-Saad S; Kubiak DW; Zhang EM; Signorelli J; Hammond SP; Mohareb AM; Luskin MR; Manne-Goehler J; Marty FM
Open Forum Infect Dis; 2022 Aug; 9(8):ofac306. PubMed ID: 35949404
[TBL] [Abstract][Full Text] [Related]
12. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
Coombs GW; Daley DA; Yee NWT; Shoby P; Mowlaboccus S
Commun Dis Intell (2018); 2022 Apr; 46():. PubMed ID: 35469556
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
Hamad Y; Nickel KB; Olsen MA; George IA
Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: posthoc analysis of a nationwide surveillance.
Ha S; Huh K; Chung DR; Ko JH; Cho SY; Huh HJ; Lee NY; Kang CI; Peck KR; Song JH;
Int J Infect Dis; 2022 Sep; 122():506-513. PubMed ID: 35752376
[TBL] [Abstract][Full Text] [Related]
15. Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection.
Schmidt-Hellerau K; Breuninger M; Kessel J; Vehreschild MJGT; Paul G; Reusch J; Jung N; Hellmich M; Fätkenheuer G
Infection; 2024 Jun; 52(3):1159-1163. PubMed ID: 38296936
[TBL] [Abstract][Full Text] [Related]
16. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
Antosz K; Battle S; Chang J; Scheetz MH; Al-Hasan M; Bookstaver PB
Pharmacotherapy; 2023 Jan; 43(1):85-95. PubMed ID: 36521869
[TBL] [Abstract][Full Text] [Related]
17. Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study.
Bavaro DF; Belati A; Diella L; Frallonardo L; Guido G; Papagni R; Pellegrino C; Brindicci G; De Gennaro N; Di Gennaro F; Denicolò S; Ronga L; Mosca A; Pomarico F; Dell'Aera M; Stufano M; Dalfino L; Grasso S; Saracino A
J Antimicrob Chemother; 2023 Sep; 78(9):2175-2184. PubMed ID: 37428015
[TBL] [Abstract][Full Text] [Related]
18. Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-Susceptible
Gilbertie J; Ulloa ER; Daiker JC; Nguyen K; Smelter D; Rose W; Geriak M; Schnabel LV; Nizet V; Sakoulas G
Open Forum Infect Dis; 2022 May; 9(5):ofac159. PubMed ID: 35493130
[TBL] [Abstract][Full Text] [Related]
19. Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis.
Allen JM; Bakare L; Casapao AM; Klinker K; Childs-Kean LM; Pomputius AF
Infect Dis Ther; 2019 Dec; 8(4):671-686. PubMed ID: 31392580
[TBL] [Abstract][Full Text] [Related]
20. Cephalotin Versus Dicloxacillin for the Treatment of Methicillin-Susceptible
Quiñonez-Flores A; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; González-Lara MF; Ponce-de-León A; Rajme-López S
Antibiotics (Basel); 2024 Feb; 13(2):. PubMed ID: 38391562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
